AI Drug Discovery Is Data-Bottlenecked, Not Compute-Bottlenecked, Startup Says

Vivodyne, a Penn spinout backed by ~$80M from Khosla Ventures, argues AI drug-discovery models lack human-relevant training data, not compute or architecture. CEO Andrei Georgescu warns that without it, AI will only "cure cancer in mice." Roughly 90% of drugs effective in animal tests fail human approval. Anthropic's Dario Amodei has called AI cancer-cure claims "more cliche than credible."